

Supplementary Table 1. Treatment regimens for comorbidities

Variable	Pemafibrate add-on (n=166)	Switch from other fibrates (n=96)	Control (n=258)	P value
Antihyperglycemic drugs				
Metformin	114 (68.7)	75 (78.1)	168 (65.1)	0.061
SGLT2 inhibitors	80 (48.2)	53 (55.2)	114 (44.2)	0.183
Sulfonylureas	22 (13.3)	18 (18.8)	41 (15.9)	0.488
Glinides	6 (3.6)	5 (5.2)	17 (6.6)	0.419
Alpha-glucosidase inhibitors	10 (6.0)	7 (7.3)	10 (3.9)	0.352
Thiazolidinediones	6 (3.6)	9 (9.4)	8 (3.1)	0.049
GLP-1 receptor agonists	10 (6.0)	14 (14.6)	29 (11.2)	0.056
Insulin treatment	27 (16.3)	11 (11.5)	33 (12.8)	0.492
Antihypertensive drugs				
ACE inhibitor/ARB	89 (53.6)	47 (38.9)	138 (53.5)	0.725
Antihyperlipidemic drugs				
Statins	113 (68.1)	60 (62.5)	146 (56.6)	0.058
Fibrates	0	96 (100.0)	75 (29.1)	<0.001
Ezetimibe	17 (10.2)	15 (15.6)	32 (12.4)	0.439

Values are presented as number (%). *P* values were obtained using Fisher's exact test.

SGLT2, sodium glucose transporter-2 inhibitor; GLP-1, glucagon-like peptide-1; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.